

Aza-and carba-Michael Adducts as Building Blocks in Heterocyclic Synthesis

Maher.A.EL-Hashash, Sameh. A. Rizk, and Yaser A.El-Badry

Department of Chemistry, Faculty of Science, University of Ain Shams, Cairo, Egypt

Email: Samehrizk2006@gmail.com

Abstract – The present work deals with the reaction of 4-(4-bromo phenyl oxobut-2-enoic acid **1** with nitrogen and carbon nucleophiles afforded aza-and carb-Michael adducts **2, 3, 6, 9, 10, 11, 12, 13, 14** depending on the type of reagents and medium (neutral or basic). The adducts **2** are used as a key starting materials to synthesize some heterocycles include furanone **15**, oxazinone **16** and pyridazinone **17** derivatives. The behavior of the latter compounds towards different electrophilic and nucleophilic reagents were investigated. Hydrazinoylation of the carba-Michael adduct **6** afforded tetrahydrobenzo[1,2-diazapene derivatives **7, 8**. The structure of the newly synthesized compounds were elucidated by elemental analysis and spectroscopic data

Keywords – 4- Bromo phenyl oxobut-2-enoic acid, Pyrazolone, Quinazolinone, Pyridoquinazoline quinoxaline, Furanone, oxazinone, Tetrahydroquinoline, 1, 2-Benzodiazapine, Pyridazinone

1. Introduction

β -aroylacrylic acids have an antiproliferative action against the human cervix carcinoma (Hela cells) [1], cytostatic activity used as an aid to study and determine factors affecting the human eye's UV filters [2], as aspergillus controller [3] and inhibitors of phospholipase [4]. Moreover they have a marked increase in vitro-activity against gram positive bacteria [5] and anticancer [6]. They are used as a key starting material due to their high electrophilicity, where the β -aroylacrylic acids react readily with nucleophiles including nitrogen and carbon nucleophiles afford either cyclic or normal Michael adducts depending on the nature of the attacking nucleophiles and the reaction medium (neutral,basic,acidic). As the Michael addition reaction may be considered an efficient tandem strategy for the construction of ring structures [7]-[9]. Therefore, this starting material will be directed to prepare the more interesting heterocyclic compounds of important biological activities which bearing 3 (2H)-pyridazinone moiety [10].

2. Materials and Method

All melting points are uncorrected and were determined on a Stuart electric melting point apparatus. Elemental analyses were carried out at the Micro analytical Center, National Research Center, Cairo, Egypt. By Elementar Viro El Microanalysis IR spectra (KBr) were recorded on infrared spectrometer FT-IR 400D using OMNIC program and are reported frequency of absorption in terms of cm^{-1} and H-NMR spectra recorded on a Bruker spectrophotometer at 400 MHz using TMS as internal standard and with residual signals of the deuterated solvent $\delta = 7.26$ ppm for CDCl_3 and $\delta = 2.51$ ppm for DMSO-d_6 . C-NMR spectra were recorded on the same spectrometer at 100 MHz and referenced to solvent signals $\delta = 77$ ppm for CDCl_3 and $\delta = 39.50$ ppm for DMSO-d_6 . DEPT 135 NMR spectroscopy were used where appropriate to aid the assignment of signals in the H and C-NMR spectra. The mass spectra were

recorded on Shimadzu GCMS-QP-1000 EX mass spectrometer at 70 e.v using the electron ionization technique. Homogeneity of all compounds synthesized was checked by TLC.

2.1. General Procedure of starting Material in literature [11]

2.1.1. Compounds 2a-c

A mixture of 3-(4-bromobenzoyl)-prop-2-enoic acid (2.55 g; 0.01 mol) and 3, 5-dimethylpyrazole, 3-methyl and/or phenylpyrazol-2-en-5-one (0.01 mol) in 50 mL ethanol was refluxed for 3 h. The reaction mixture was allowed to cool and the crude product was washed by petroleum ether (Boiling point: 40- 60 $^{\circ}\text{C}$), and then, crystallized from toluene to give compounds **2**

2.1.2. 4-(p-bromophenyl)-2-(3,5-dimethylpyrazol-1-yl)-4-oxobutanoic acid (2a)

Yield 83%. Melting point 165-167 $^{\circ}\text{C}$. IR (KBr) 1680, 1720 (CO). $^1\text{H-NMR}$ spectrum (CDCl_3) : δ 2.06 (s,3H,CH₃), 2.20 (s,3H,CH₃), 3.81(2dd,1Ha, (J=15.2, J=7.2) and 1Hb methylene protons, CH₂-C=O, (J=15.2, J=5.1) diastereotopic protons), 4, 8 (dd,CH-COO,sterogenic methine proton , J=7.2, J=5.1), multiplet at 7.47 – 7.75 assigned for 4ArH aromatic protons, singlet 13.2 an acidic proton which exchanged in D_2O and $^{13}\text{C-NMR}$ δ 13.8 (CH₃), 21.3 (CH₃), 34.4 (CH₂), 58.4 (CH), 102.3 (CH), 128.2 (CH), 129.2 (CH), 129.5 (CH), 134.4(C), 138.1(C), 142.7(C), 145.0 (C), 173.2(C), 198.5(C). Anal.Calc. for $\text{C}_{15}\text{H}_{15}\text{BrN}_2\text{O}_3$:C51.30, H 4.31; found: C51.26, H 4.29. MS: m/z 353[M+2], 351[M], 307, 198, 154, 105, 96.

2.1.3. 4-(p-bromophenyl)-2-(3-methyl-5-oxo-4, 5-dihydropyrazol-1-yl)-4-oxobutanoic acid (2b)

Yield 74 %.Mp 180-181 $^{\circ}\text{C}$. IR (KBr) 1617, 1630 (C=N), 1667, 1691, 1705(CO). $^1\text{H-NMR}$ spectrum (CDCl_3) : δ 2.10(s,3H,CH₃),2.09(s,2H,CH₂),3.73 (2dd,1Ha, (J=15.2,

J=7.2) and 1Hb methylene protons, CH₂-C=O, (J=15.2, J=5.1) diastereotopic protons), 4, 90 (dd, CH-COO, stereogenic methine proton, J=7.2, J=5.1), 7.47 – 7.74 (m, 4H, 4ArH aromatic protons), 12.8 (brs, 1H, OH, an acidic proton which exchanged in D₂O) and ¹³C-NMR δ 16.8 (CH₃), 34.7 (CH₂), 44.4 (CH), 53.4 (CH), 128.9 (C), 131.2 (CH), 132.5 (CH), 135.4 (C), 154.8 (C), 171.7 (C), 199.0 (C). Anal. Calc. for C₁₄H₁₃BrN₂O₄: C 47.61, H 3.71; found: C 47.54, H 3.89.

2.1.4. 4-(p-bromophenyl)-2-(3-phenyl-5-oxo-4, 5-dihydropyrazol-1-yl)-4-oxobutanoic acid (2c)

Yield 81 %. Mp 169-171 °C. IR (KBr) 1630 (C=N), 1681, 1722 (CO), 3244 (OH). ¹H NMR (CDCl₃): δ 3.38 (s, 2H, CH₂), 3.71 (2dd, 1Ha, (J=15.2, J=7.2) and 1Hb methylene protons, CH₂-C=O, (J=15.2, J=5.1) diastereotopic protons), 4.95 (dd, CH-COO, stereogenic methine proton, J=7.2, J=5.1), 5.76 (s, 1H, pyrazole proton), 7.47 – 7.97 (m, 9H, 9ArH aromatic protons), 13.8 (brs, 1H, OH, an acidic proton which exchanged in D₂O) and ¹³C-NMR δ 35.7 (CH₂), 43.4 (CH), 53.7 (CH), 125.9 (2CH), 126.2 (CH), 128.5 (2CH), 129.2 (C), 132.2 (2CH), 132.8 (2CH), 134.8 (C), 136.4 (C), 143.1 (C), 168.5 (C), 171.7 (C), 199.6 (C). Anal. Calc. for C₁₉H₁₅BrN₂O₄: C 54.96, H 3.64; found: C 55.04, H 3.59.

2.1.5. 4-(p-bromophenyl)-2-(3-phenyl-5-oxo-4,5-dihydro-1H-pyrazol-4-yl)-4-oxobutanoic acid 3

The 3-(4-bromobenzoyl)-prop-2-enoic acid (2.55 g; 0.01 mol) was added to a stirred suspension of, 3-phenylpyrazol-2-en-5-one (1.60 g, 0.01 mol) in 50% sodium hydroxide (2 mL) in 20 mL ethanol. The reaction mixture was stirred at room temperature for 2 days, and the crude product was quenched with H₂O and extracted with diethyl ether. The aqueous layer was acidified by dil. HCl. The solid that separated was filtered off, washed by petroleum ether (b.p 40-60 °C), dried and then, crystallized from benzene afford Michael adduct 3

Yield 66%. Mp 185-187 °C. IR (KBr) 1680, 1720 (CO), 3265 (NH). ¹H NMR (DMSO-d₆): δ 3.51 (2dd, 1Ha, (J=15.2, J=7.2) and 1Hb methylene protons, CH₂-C=O, (J=15.2, J=5.1) diastereotopic protons), 3.80 (dd, CH-COO, stereogenic methine proton, J=7.2, J=5.1), 4.56 (d, 1H, CH), multiplet at 7.47 – 7.95 assigned for 9ArH aromatic protons, singlet 10.2 an acidic NH proton which exchanged in D₂O and ¹³C-NMR δ 38.4 (CH), 39.6 (CH₂), 52.9 (CH), 125.3 (2CH), 127.2 (CH), 128 (2CH), 129.2 (C), 132.5 (2CH), 132.4 (2CH), 134.1 (C), 135.7 (C), 161.0 (C), 173.2 (C), 176.3 (C), 193.5 (C). Anal. Calc. For C₁₉H₁₅BrN₂O₄: C 54.96, H 3.64; found: C 55.01, H 3.68. MS: m/z 371 [M-CO₂], 295, 218, 185, 105.

2.1.6. Compounds 4, 5

An equimolar mixture of 3-(4-bromobenzoyl)-prop-2-enoic acid (2.55 g; 0.01 mol), 3-methyl pyrazol-2-en-5-one (1.20 g; 0.01 mol) and anhydrous AlCl₃ (0.01 mol) in 50 mL benzene. The reaction mixture was heated in water bath for 3 h, and the reaction mixture was left over night and then decomposed with ice/HCl. The excess solvent removed by steam distillation. The solid that separated was filtered off, washed by petroleum ether (B.p 40-60 °C), dried and then, crystallized from toluene afford 5, ethanol afford 4

2.1.7. 4-(p-bromophenyl)-2-(5-phenyl-3-hydroxy-3, 4-dihydro-pyrazol-4-yl)-4-oxobutanoic acid 4

Yield 37%. Mp 190-192 °C. IR (KBr) 1613 (C=N), 1670, 1685, 1715 (CO), 3245 (NH), 3410 (OH). ¹H NMR (CDCl₃): δ 3.51 (2dd, 1Ha, (J=15.2, J=7.2) and 1Hb methylene protons, CH₂-C=O, (J=15.2, J=5.1) diastereotopic protons), 3.80 (2dt, CH-COO, stereogenic methine proton, J=8.7, J=7.2, J=5.1), 4.56 (d, 1H, CH stereogenic methine proton of pyrazol, J=8.7), multiplet at 7.47 – 7.95 assigned for 9ArH aromatic protons, singlet 10.2 an acidic OH=NH proton and 11.3 assigned for COOH which exchanged in D₂O and ¹³C-NMR δ 15.7 (CH₃), 39.4 (CH), 40.6 (CH₂), 100.5 (CH), 127.3 (CH), 127.4 (CH), 128 (CH), 129.2 (C), 130.5 (C), 131.4 (CH), 134.1 (C), 161.0 (2C), 170.2 (C). Anal. Calc. For C₁₄H₁₃BrN₂O₄: C 47.59, H 3.68; found: C 47.85, H 3.35. MS: m/z 354 [M+2], 352 [M], 334, 138, 105.

2.1.8. 4-[(2-(p-bromophenyl)-2-oxoethyl] 3-methyl-furo [2, 3-c] pyrazol-5(4H)-one 5

Yield 40%. Mp 165-167 °C. IR (KBr) 1613 (C=N), 1685, 1745 (CO), 3245 (NH). ¹H NMR (CDCl₃): δ 3.71 (dd, 2H, (J=16.8, J=11.2), CH₂) 4.16 (t, furanone proton, J=11.2), multiplet at 7.57 – 7.95 assigned for 9ArH aromatic protons, singlet 10.6 an acidic NH proton which exchanged in D₂O and ¹³C-NMR δ 20.2 (CH₃) 39.4 (CH), 40.6 (CH₂), 100.5 (CH), 127.3 (CH), 127.4 (CH), 128 (CH), 129.2 (C), 130.5 (C), 131.4 (CH), 134.1 (C), 161.2 (C), 166.2 (C), 179.2 (C). Anal. Calc. For C₁₄H₁₁BrN₂O₃: C 50.15, H 3.28; found: C 50.85, H 3.12. MS: m/z 336 [M+2], 334 [M], 214, 138, 105.

2.1.9. Compounds 6a, b

The 3-(4-bromobenzoyl)-prop-2-enoic acid (2.55 g; 0.01 mol) was added to a stirred suspension of, cyclohexanone and/or camphor (0.01 mol) in 50% sodium hydroxide (2 mL) in 20 mL ethanol. The reaction mixture was stirred at room temperature for 2 days, and the crude product was quenched with H₂O and extracted with diethyl ether. The aqueous layer was acidified by dil. HCl. The semisolid that separated was filtered off, washed by ether, dried, slow evaporation, and then, crystallized from benzene afford Michael adduct 19.

2.1.10. 4-(p-bromophenyl)-2-(2-oxo-cyclohexyl)-4-oxobutanoic acid 6a

Yield 60 %. Mp 160-162 °C. IR (KBr) 1680, 1704, 1720 (CO), 3422 (OH). ¹H NMR (DMSO-d₆): 1.34-1.73 (m, 6H, 3CH₂ of cyc. hexyl proton), 2.03-2.27 (m, 2H, CH₂CO, cyc. hexyl proton), 2.63-2.75 (m, 1H, stereogenic methine proton of cyc. hex.) 3.17 (2dd, CH-COO, stereogenic methine proton J=9.1, J=7.9, J=2.4), 3.56 (2dd, 1Ha, (J=15.2, J=7.) and 1Hb methylene protons, CH₂-C=O, (J=15.2, J=2.4) diastereotopic protons), 7.43-7.56 (m, 4H, Ar-H), 11.30 (brs, 1H, OH) and ¹³C-NMR δ 20.8 (CH₂), 24.3 (CH₂), 24.7 (CH₂), 39.9 (CH₂), 40.4 (CH), 41.3 (CH₂), 51.4 (CH), 129.3 (C), 130.8 (2CH), 135.2 (C), 178.2 (C), 194.7 (C), 208.4 (C). Anal. Calc. For C₁₆H₁₇BrO₄: C 54.41, H 4.85; found: C 54.67, H 4.55. MS: m/z 292 [M-(CO₂+OH)], 156, 137, 105.

2.1.11. 4-(p-bromophenyl)-2-(4, 7, 7-trimethyl-3-oxo-bicyclo [2, 2, 1] hepta-2-yl)-4-oxobutanoic acid 6b

Yield 65 %. Mp 197-198 °C. IR (KBr) 1690, 1710

,1759(CO), 3362 (OH). ¹HNMR (DMSO-d₆) : 0.94 (s,3H, CH₃), 1.17 (s,3H,CH₃), 1.26 (s,3H,CH₃), 1.48-1.71(m,4H,2CH₂), 1.87(t,1H, methine bridgehead), 3.17 (2dd,CH-COO,sterogenic methine proton J=9.7, J=7.9,J=2.4), 3.25(dt,1H,attached,J=9.7), 3.56(2dd,1Ha,(J=15.2, J=7.9) and 1Hb methylene protons, CH₂-C=O, (J=15.2, J=2.4) diastereotopic protons), 7.48-7.56 (m,4H,Ar-H), 11.34 (brs,1H,OH) and ¹³C-NMR δ 11.8 (CH₃), 18.3 (CH₃), 18.7 (CH₃), 21.9(CH₂), 26.8 (CH₂), 37.3 (CH₂), 38.4 (CH), 44.6 (CH), 45.8 (CH), 48.2(C), 56.8 (C), 129.7 (C), 130.4(2CH), 131.8 (2CH), 136.2(C), 178.8 (C), 195.7 (C), 213.4(C). Anal. Calc. For C₂₀H₂₃BrO₄: C 58.98, H 5.69; found: C 59.15, H 5.85. MS:m/z 346[M-(CO₂+OH)], 267,175,156,137.

2.1.12. Compounds 7, 8

A mixture of 6a, b (0.01 mol) and hydrazine hydrate and/or phenyl hydrazine (0.01mol) in ethanol (30 mL) and was heated under reflux for 5h. The reaction mixture was allowed to cool and the separated product was filtered, dried and were recrystallized from ethanol.

2.1.13. 3-(p-bromophenyl)-1-phenyl-4,5,6,7,8,9-hexahydro-1H-benzoc[1,2-diazepine-5-carboxylic acid 7

Yield 75 %.M.p 140-141 °C. IR (KBr) 1620(C=N), 1687 (CO), 3390 (OH). ¹HNMR (DMSO-d₆) : 1.36-1.45(m,H,CH₂), 1.67-1.89 (m,4H,2CH₂), 2.14-2.30 (m,2H,CH₂), 3.16 (oct,2H, methylene protons, CH₂-C=O, diastereotopic protons) 3.17 (m,CH-COO,sterogenic methine proton), 6.88-7.46 (m,4H,Ar-H), 10.60 (brs,1H,OH) and ¹³C-NMR δ 22.6 (CH₂), 26.1 (CH₂), 27.7 (CH₂), 31.1 (CH₂), 40.7 (CH₂), 46.3(CH), 112.4 (C), 117.3 (2CH), 121.5 (C), 123.1 (CH), 128.8 (2CH), 131.9(2CH), 135.2 (C), 137.7 (C), 144.4(C), 147.7 (C), 171.4(C). Anal. Calc. For C₂₂H₂₁BrN₂O₂: C 62.13, H 4.98; found: C 62.54, H 4.36. MS:m/z 379[M-(CO₂)], 303,228,156,149,105.

2.1.14. 3-(p-bromophenyl)-1-phenyl-4,5,6,7,8,9-hexahydro-1H-benzoc[1,2-diazepine-5-carboxylic acid 8

Yield 81 %.M.p 129-131 °C. IR(KBr) 1617(C=N), 1577 (CO), 3143 (NH), 3405 (OH). : 0.94 (s,3H, CH₃), 1.07 (s,3H,CH₃), 1.12 (s,3H,CH₃), 1.43-1.51(m,2H,CH₂), 1.73-1.86(m,2H,CH₂), 1.99(t,1H, methine bridgehead, J=9.4Hz), 2.57 (2dd,CH-COO,sterogenic methine proton,J=7.9, 6.5, 2.4 Hz), 2.85 (dt,1H,attached,J=9.4, 6.5Hz), 3.56 (2dd,1Ha,(J=15.2, J=7.9) and 1Hb methylene protons, CH₂-C=O, (J=15.2, J=2.4) diastereotopic protons), 7.48-7.56 (m,4H,Ar-H), 9.84 (brs,1H,NH) 12.23 (brs,1H,OH) and ¹³C-NMR δ 14.6 (CH₃), 18.1 (CH₃), 20.7 (CH₃), 22.1 (CH₂), 30.7 (CH₂), 41.1(CH₂), 44.4 (CH), 46.3 (CH), 50.5 (C), 53.1 (C), 120.8 (C), 122.9(C), 130.2 (2CH), 131.7 (2CH), 136.4(C), 145.7 (C), 150.4(C), 171.1(C). Anal. Calc. for C₂₀H₂₃BrN₂O₂: C 59.56, H 5.75; found: C 59.70, H 5.47.

2.1.15. Compounds of 9

The 3-(4-bromobenzoyl)-prop-2-enoic acid (2.55 g; 0.01 mol) was added to a stirred suspension of, 2-methyl-4(3H)-quinazolinone and/or 2-methyl-6, 8-dibromo-4(3H)-quinazolinone (0.01 mol) in 30 mL ethanol. The reaction mixture was heated under reflux for 4h and concentrated under reduced pressure. The solid that separated after cooling

was filtered off, washed by petroleum ether (B.p 40- 60 °C), dried and then, crystallized from ethanol.

2.1.16. 4-(p-bromophenyl)-2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-4-oxo-butanoic acid (9a)

Yield 73%.M.p 189-191 °C. IR (KBr) 1680, 1702 (CO), 3200(OH). ¹HNMR (DMSO-d₆) : δ 2.3(s,3H,CH₃), 3.81 (2dd,1Ha,(J=15.2,J=8.2) and 1Hb methylene protons, CH₂-C=O, (J=15.2, J=5.1) diastereotopic protons), 4.55 (dd,CH-COO,sterogenic methine proton, J=8.2,J=5.1), 7.45-7.90(m,8H, aromatic protons) and ¹³C-NMR δ 15.4 (CH₃), 42.1 (CH₂), 57.5 (CH), 118.5 (C), 126.8(2CH), 127.4 (CH), 128.3 (CH), 129.3 (CH), 131.2(2CH), 137.2 (CH), 139 (C H), 141.4(C), 149 (C), 158.4 (C), 160.8 (C), 173.7(C), 194.5 (C). Anal. Calc. For C₁₉H₁₅BrN₂O₄: C 54.96, H 3.64; found: C 55.41, H 3.86. MS:m/z 232,198,187,105.

2.1.17. 4-(p-bromophenyl)-2-(6,8-dibromo-2-methyl-4-oxo-4H-quinazolin-3-yl)-4-oxo-butanoic acid(9b)

Yield 78%.M.p 216-218 °C. IR (KBr) 1668, 1695 (CO), 3350(OH). ¹HNMR (DMSO-d₆) : δ 2.20(s,3H,CH₃), 3.82 (2dd,1Ha,(J=15.2,J=8.2) and 1Hb methylene protons, CH₂-C=O, (J=15.2, J=5.1) diastereotopic protons), 4.83 (dd,CH-COO,sterogenic methine proton, J=8.2,J=5.1), 7.45-7.80(m,6H, aromatic protons) and ¹³C-NMR δ 16.4 (CH₃), 36.1 (CH₂), 57.5 (CH), 117.5 (C), 126.8(C), 127.4 (C), 128.3 (CH), 129.3 (CH), 131.2(2CH), 137.2 (2CH), 139 (C), 141.4(CH), 149 (C), 159.4 (C), 161.8 (C), 170.7(C), 196.5 (C). Anal. Calc. For C₁₉H₁₃Br₃N₂O₄: C 39.82, H 2.29; found: C 40.20, H 2.86. MS:m/z 376 (Br-C₆H₄-COCH₂), 244,201,105.

2.1.18. 3-[2-(p-bromophenyl)-2-oxoethyl](3,4-dihydro-1H-quinoxalin-2-one(10)

A mixture of 3-(4-bromobenzoyl)-prop-2-enoic acid (2.55 g; 0.01 mol) and o-phenylene diamine (1.08 g; 0.01 mol) in 30 mL ethanol was refluxed for 4 h. The reaction mixture was allowed to cool and the crude product was washed by petroleum ether (b.p 40- 60°C), and then, crystallized from ethanol.

Yield 83%.M.p 158-160 °C. IR(KBr) 1673,1685 (CO), 3100(NH). ¹HNMR (DMSO-d₆) : δ 3.62 (2dd,1Ha,(J=15.2,J=9.2) and 1Hb methylene protons, CH₂-C=O, (J=15.2, J=3.4) diastereotopic protons), 4.87 (dd,CH-COO,sterogenic methine proton, J=9.2,J=3.4), 7.5-7.90(m,8H, aromatic protons) 9.80 (brs,1H,NH) 11.87 (brs,1H,NH amide) and ¹³C-NMR δ 34.1 (CH₂), 57.4 (CH), 114.5 (CH), 118.5 (CH), 120.8(CH), 123.4 (CH), 128.3 (C), 129.8 (C), 133.2(2CH), 135.2 (2CH), 136.7 (C), 140.4(C), 165.4 (C), 193.5 (C). Anal. Calc. for C₁₆H₁₃BrN₂O₂: C 55.67, H 3.80; found: C 55.09, H 3.46. MS:m/z 347[M+2], 345 (M), 198,147,130.

2.1.19. 1-(p-bromophenyl)-5-oxo-7, 9-dibromo- pyrido[2,1-b]quinazolin-4-carboxylic acid(11)

The 3-(4-bromobenzoyl)-prop-2-enoic acid (2.55 g; 0.01 mol) was added to a stirred suspension of, 2-methyl-4(3H)-quinazolinone (1.6 g; 0.01 mol) in the presence of sodium methoxide (2mL, 5 g sodium in 10mL methanol) in 30 mL methanol. The reaction mixture was stirred at room temperature for 3 days, and the crude product was quenching

with H₂O and extracted with diethyl ether. The aqueous layer was acidified by dil.HCl. The reaction mixture was heated under reflux for 2h in water bath. The separated solid was filtered, dried and was crystallized from toluene.

Yield 73%. M.p 170-172 °C. IR (KBr) 1663, 1705 (CO), 3400(OH). ¹HNMR (DMSO-d₆) : δ 2.62 (2dd, 1Ha, (J=15.2, J=8.2) and 1Hb methylene protons, CH₂-C=O, (J=15.2, J=3.4) diastereotopic protons), 3.69 (dd, CH-COO, stereogenic methine proton, J=8.2, J=3.4), 7.26-7.89(m, 7H, aromatic protons) 12.2 (brs, 1H, COOH) and ¹³C-NMR δ 42.1 (CH), 55.0(CH₂), 98.4 (CH), 104.5 (CH), 118.5 (CH), 120.8(CH), 125.4 (CH), 129.3 (CH), 129.8 (C), 130.2(CH), 135.2 (C), 139 (C), 140 (C), 141.4(C), 145 (C), 148.4 (C), 160.8 (C), 176.7(C), 194.5 (C). Anal.Calc. For C₁₉H₁₁BrN₂O₃: C 41.08, H 2.00; found: C 41.26, H 2.16.

2.1.20. 1-(p-bromophenyl)-6-hydroxy-pyrido [1, 2-a] quinazolin-3-carboxylic acid (12)

The 3-(4-bromobenzoyl)-prop-2-enoic acid (2.55 g; 0.01 mol) was added to a stirred suspension of, 2-methyl-4(3H)-quinazolinone (1.6 g; 0.01 mol) in the presence of few drops piperidine in 30 mL acetonitrile. The reaction mixture was heated under reflux for 2h in water bath. The reaction mixture was poured onto ice/HCl and the separated solid was filtered, dried and was crystallized from toluene.

Yield 73%. M.p 145-146 °C. IR (KBr) 1663, 1705 (CO), 3400(OH). ¹HNMR (DMSO-d₆) : δ 2.50(s, 1H, methine proton), 7.05-8.20(m, 10H, aromatic protons) 11.2(s, 1H, COOH), 13.2 (brs, 1H, OH=NH, lactam-lactim dynamic equilibrium) and ¹³C-NMR δ 42.1 (CH), 98.4 (CH), 104.5 (CH), 118.5 (CH), 120.8(CH), 125.4 (CH), 129.3 (CH), 129.8 (2CH), 130.2(2CH), 135.2 (C), 139 (C), 141.4(C), 145 (C), 148.4 (C), 160.8 (C), 176.7(C), 194.5 (C). Anal.Calc. For C₁₉H₁₃BrN₂O₃: C 57.45, H 3.30; found: C 57.29, H 3.16. MS:m/z 337[M-(CO₂+OH)], 180, 156, 105.

2.1.21. Compounds 13a-c

A mixture of 2a-c (0.01 mol) and acetic anhydride (9.4 mL, 0.1mol) and then refluxed on water bath for 2h. The excess acetic anhydride was removed by distillation and the separated product was filtered, dried and were recrystallized from mix toluene-ethanol to give compounds

2.1.22. 3,5-dimethyl 1N-[(5-(p-bromophenyl)-2-oxo-fur-3-yl)]pyrazole (13a)

Yield 90%. M.p 261-263 °C. IR (KBr) 1765 (CO). ¹HNMR (DMSO-d₆) : δ 2.18(s, 3H, CH₃), 2.2(s, 3H, CH₃), 3.71(dd, 2H, (J=16.8, J=11.2), CH₂) 5.42 (d, furanone proton, J=4.2), 6.18(d, CH-furanone, J=4.2) multiplet at 7.40 – 7.55 assigned for 4ArH aromatic protons, singlet and ¹³C-NMR δ 10.3 (CH₃), 13.7(CH₃), 63.4 (CH), 81.6 (CH), 102.5 (CH), 123.3 (C), 127.4 (2CH), 130 (2CH), 137.2 (C), 139.5 (C), 144.1(C), 175.7(2C). Anal.Calc. For C₁₅H₁₃BrN₂O₂: C 54.07, H 3.3; found: C 54.41, H 3.26. MS:m/z 335 [M+2], 333 [M], 238, 156, 96.

2.1.23. 3-methyl 1N-[(5-(p-bromophenyl)-2-oxo-fur-3-yl)]pyrazol-5(4H)-one (13b)

Yield 83%. M.p 273-275 °C. IR (KBr) 1695, 1790 (CO).

¹HNMR (DMSO-d₆) : δ 2.3(s, 3H, CH₃), 3.71(s, 2H, CH₂ pyrazol), 5.42 (d, furanone proton, J=4.2), 6.33(d, CH-furanone, J=4.2) multiplet at 7.40 – 7.55 assigned for 4ArH aromatic protons, singlet and ¹³C-NMR δ 15.1(CH₃), 43.4 (CH₂), 62.1 (CH), 93.5 (CH), 124.5 (C), 127.4 (2CH), 128.3 (2CH), 129.3 (2CH), 137.2 (CH), 141.4(C), 173.7(C). Anal.Calc. For C₁₄H₁₁BrN₂O₃: C 50.15, H 3.28; found: C 51.41, H 3.26. MS:m/z 337 [M+2], 335 [M], 214, 138, 105, 77.

2.1.24. 3-phenyl 1N-[(5-(p-bromophenyl)-2-oxo-fur-3-yl)]pyrazol-5(4H)-one (13c)

Yield 83%. M.p 295-297 °C. IR (KBr) 1695, 1806 (CO). ¹HNMR (DMSO-d₆) : δ 3.45(s, 2H, CH₂ pyrazol), 5.42 (d, furanone proton, J=4.2), 6.33(d, CH-furanone, J=4.2) multiplet at 7.40 – 7.55 assigned for 4ArH aromatic protons, singlet and ¹³C-NMR δ 43.4 (CH₂), 62.1 (CH), 93.5 (2CH), 123.5 (C), 124.8(2CH), 127.4 (2CH), 128.3 (2CH), 129.3 (2CH), 137.2 (C), 139 (2C), 141.4(C), 169 (C), 173.7(C). Anal.Calc. For C₁₉H₁₃BrN₂O₃: C 57.45, H 3.3; found: C 57.41, H 3.26. MS:m/z 399 [M+2], 397 [M], 320, 241, 160, 77.

2.1.25. Compounds 16a-c

A mixture of 2a-c (0.01 mol) and hydroxyl amine (1.03 g; 0.015mol) in pyridine (20 mL) and then refluxed for 3h. The reaction mixture was poured onto ice/HCl and the separated solid was filtered, dried and were recrystallized from ethanol

2.1.26. 3-(p-bromophenyl)-5-(3, 5-dimethylpyrazol-1-yl)-6-oxo-4, 5-dihydro-1, 2-oxazine (14a)

Yield 90%. M.p 151-153 °C. IR (KBr) 1645(C=N), 1765 (CO). ¹HNMR (CDCl₃) : δ 1.99(s, 3H, CH₃), 2.24(s, 3H, CH₃), 3.81 (2dd, 1Ha, (J=15.2, J=8.2) and 1Hb methylene protons, CH₂-C=O, (J=15.2, J=5.1) diastereotopic protons in oxazine ring), 4.95 (dd, CH-COO, stereogenic methine proton, J=8.2, J=5.1), 5.76(s, 1H, pyrazole proton) multiplet at 7.60 – 7.85 assigned for 4ArH aromatic protons, singlet and ¹³C-NMR δ 11.3 (CH₃), 13.7(CH₃), 63.4 (CH), 32.6 (CH₂), 53.5 (CH), 100.3 (CH), 127.4 (2C), 130 (2CH), 137.2 (C), 139.5 (C), 144.1(C), 163.6 (C), 175.7(C). Anal.Calc. For C₁₅H₁₄BrN₃O₂: C 51.74, H 4.05; found: C 51.41, H 4.26. MS:m/z 355 [M-CO₂], 191, 156, 150, 95.

2.1.27. 3-(p-bromophenyl)-5-(3-methyl-5-oxo-pyrazol-1-yl)-6-oxo-4, 5-dihydro-1, 2-oxazine (14b)

Yield 88%. M.p 142-144 °C. IR (KBr) 1685, 1733 (CO). ¹HNMR (DMSO-d₆) : δ 2.3(s, 3H, CH₃), 3.71(s, 2H, CH₂ pyrazol), 3.9 (2dd, 1Ha, (J=15.2, J=7.2) and 1Hb methylene protons, CH₂-C=O, (J=15.2, J=5.1) diastereotopic protons), 4.4 (dd, CH-COO, stereogenic methine proton, J=7.2, J=5.1), multiplet at 7.40 – 7.55 assigned for 4ArH aromatic protons, singlet and ¹³C-NMR δ 19.1(CH₃), 47.4 (CH₂), 62.1 (CH), 100.5 (CH), 124.5 (C), 126.4 (2CH), 127.3 (2CH), 129.3 (2CH), 137.2 (CH), 141.4(C), 173.7(C). Anal.Calc. For C₁₄H₁₂BrN₃O₃: C 48.00, H 3.43; found: C 48.41, H 3.50. MS:m/z 352 [M+2], 350 [M], 214, 138, 105, 77.

2.1.28. 3-(*p*-bromophenyl)-5-(3-phenyl-5-oxo-pyrazol-1-yl)-6-oxo-4,5-dihydro-1,2-oxazine(14c)

Yield 83%.Mp 200-202 °C. IR (KBr) 1695, 1738 (CO). ¹HNMR (CDCl₃) : δ 3.45(s,2H,CH₂ pyrazol), 3.91 (2dd,1Ha,(J=15.2,J=8.2) and 1Hb methylene protons , CH₂-C=O, (J=15.2, J=5.1) diastereotopic protons), 5,25 (dd,CH-COO,sterogenic methine proton , J=8.2,J=5.1) ,7.45-8.00(m,9H, aromatic protons) and ¹³C-NMR δ 30.4 (CH₂) ,42.1 (CH),52.5 (CH),125.5 (C),126.8(2CH),127.4 (2CH),128.3 (CH), 129.3 (2CH), 131.2(2CH),137.2 (C) ,139 (2C) , 161.4(C) ,169 (C) 173.7(C) .Anal.Calc. For C₁₉H₁₃BrN₂O₃: C 57.45, H 3.3; found: C 57.41, H 3.26. MS:m/z 399 [M+2],397 [M],320,241,160,77.

2.1.29. Compounds 15a-c

A mixture of 2a-c (0.01 mol) and hydrazine hydrate (1 mL, 0.015mol) in ethanol (30 mL) and was refluxed for 3h. The reaction mixture was allowed to cool and the separated product was filtered,dried and were recrystallized from ethanol.

2.1.30. 6-(4-bromophenyl)-4-(3, 5-dimethyl-pyrazol-1-yl)-4, 5-dihydropyridazin-3(2H) one 15a

Yield 90%.Mp 209-211 °C. IR (KBr) 1651 (C=N), 1675 (CO), 3200(NH). ¹HNMR (DMSO-d₆) : 2.17 (s,6H,2CH₃),δ 3.92 (2dd,1Ha,(J=15.2,J=7.9) and 1Hb methylene protons , CH₂-C=O, (J=15.2, J=2.4) diastereotopic protons), 5.37 (dd,CH-COO,sterogenic methine proton , J=7.9,J=2.4),5.86 (s,1H,CH-pyrazol) ,7.53 (d,2H J=8.1,Ar-H) , 7.96(d,2H, J=8.1,ArH) 10.85 (brs,1H,NH) and ¹³C-NMR δ 13.9 (CH₃), 16.7 (CH₃),33.4 (CH₂) ,55.5 (CH),108.5 (CH),126.3(C),130.4 (2CH),132.3 (2CH), 139.8 (C), 138.2(2CH),150.2 (C) ,154.7 (C) , 163.4(C) .Anal.Calc. For C₁₅H₁₅BrN₄O: C 51.89, H 4.35; found: C 51.78, H 4.46. MS:m/z 268[M-Br],250 (M-3,5-dimethylpyrazole),224,195,143,115.

2.1.31. 6-(4-bromophenyl)-4-(3methyl-5-oxo-4, 5-dihydropyrazol-1-yl)-4, 5-dihydropyridazin-3(2H) one 15b

Yield 86%.Mp 230-232 °C. IR(KBr) 1651 (C=N),1673 (CO),3220-3310(NH). ¹HNMR (DMSO-d₆) : 1.97 (s,3H, CH₃),3.32 (s,2H,CH₂ of pyrazol), 3.86 (2dd,1Ha,(J=15.2,J=7.9) and 1Hb methylene protons , CH₂-C=O, (J=15.2, J=2.4) diastereotopic protons), 4.47 (dd,CH-COO,sterogenic methine proton , J=7.9,J=2.4),7.53 (d,2H J=8.1,Ar-H) , 7.96(d,2H, J=8.1,ArH) 11.75 (brs,1H,NH) and ¹³C-NMR δ 19.7 (CH₃),32.4 (CH₂) ,44.5 (CH₂),54.6 (CH),125.3(C),130.4 (2CH),132.3 (2CH), 136.8 (C), 158.2(C),160.2 (C) ,164.7 (C) , 169.4(C) .Anal.Calc. For C₁₄H₁₃BrN₄O₂ : C 48.16,H 3.75;found: C 48.48 , H 3.40.

2.1.32. 6-(4-bromophenyl)-4-(3-phenyl-5-oxo-4, 5-dihydropyrazol -yl)-4, 5-dihydropyridazin-3(2H) one 15c

Yield 86%.Mp 238-240 °C. IR (KBr) 1651 (C=N), 1679 (CO), 3220 (NH). ¹HNMR (DMSO-d₆) : 3.58 (s,2H,CH₂ of pyrazol), 3.76 (2dd,1Ha,(J=15.2,J=7.9) and 1Hb methylene protons , CH₂-C=O, (J=15.2, J=2.4) diastereotopic protons), 3.99 (dd,CH-COO,sterogenic methine proton , J=7.9,J=2.4),7.23-7.9 (m,9H, ,ArH) 11.89 (brs,1H,NH) and ¹³C-NMR δ 32.4 (CH₂) ,44.2 (CH₂),55.6 (CH),125.7(C),126.4 (2CH),130.3 (2CH), 132.8 (CH),

138.2(2CH),140.2 (2CH) ,144.7 (C) , 149.4(C) 154.2 (C) ,158.7 (C) , 161.4(C) 168.4(C) .Anal.Calc. For C₁₉H₁₅BrN₄O₂: C 55.49, H 3.68; found: C 55.69, H 3.60.

2.1.33. 6-(4-bromophenyl)-3-chloro-4-(3, 5-dimethyl-pyrazol-1-yl)-4, 5-dihydropyridazin-3(2H) one 16

A mixture of 15a (3.47 g; 0.01 mol) and phosphorous pentachloride (1 g, 0.015mol) in phosphorous oxy chloride (20 mL) and was heated at 60 C in reflux for 2h. The excess oxy chloride was removed by vacuum distillation, and the reaction mixture was diluted with ice/H₂O. The separated product was washed,filtered,dried and was crystallized from toluene.

Yield 80%.Mp 181-183 °C. ¹HNMR (DMSO-d₆) : δ 2.17 (s,6H, 2CH₃), 3.72 (2dd,1Ha,(J=15.2,J=7.9) and 1Hb methylene protons , CH₂-C=O, (J=15.2, J=2.4) diastereotopic protons), 5.37 (dd,CH-COO,sterogenic methine proton , J=7.9,J=2.4),5.96 (s,1H,CH-pyrazol) ,7.33 (d,2H J=8.1,Ar-H) , 7.76(d,2H, J=8.1,ArH) , and ¹³C-NMR δ 12.9 (CH₃), 15.7 (CH₃), 29.5 (CH₂),54.5 (2CH), 101.3 (CH), 126.8 (C), 132.2(2CH),134.2 (2CH) ,139.7 (C) , 141.7 (C) 153.4(C) , 154.7(C) , 165.7(C) .Anal.Calc. For C₁₅H₁₄BrClN₄: C 49.27, H 5.86; found: C 49.45, H 3.66. MS:m/z 332[M+2-Cl],330 ,175,156,95.

2.1.34. 6-(4-bromophenyl)-3-(2-oxoethylamino)-4-(3, 5-dimethyl-pyrazol-1-yl)-4, 5-dihydropyridazin-3(2H) one 17

A mixture of 16 (3.66 g; 0.01 mol) and ethanol amine (0.92 g, 0.015mol) in n-butanol(20 mL) and was heated under reflux for 4h. The reaction mixture was leaved overnight. The solid that separated was washed,filtered,dried and recrystallized from n-butanol.

Yield 83%.Mp 204-206 °C. 1651 (C=N),1680 (CO) 3498 (NH)/(OH) ¹HNMR (DMSO-d₆) : δ 2.07 (s,3H, CH₃), 2.27 (s,3H, CH₃), 3.51 (t,2H,CH₂-N,J=6.4),3.72 (2dd,1Ha,(J=15.2,J=7.9) and 1Hb methylene protons , CH₂-C=O, (J=15.2, J=2.4) diastereotopic protons),3.90 (t,2H,CH₂-OH),4.84 (brs,1H,OH,J=6.4), 5.37 (dd,CH-COO,sterogenic methine proton , J=7.9,J=2.4),5.96 (s,1H,CH-pyrazol) ,7.33 (d,2H J=8.1,Ar-H) , 7.76(d,2H, J=8.1,ArH) ,8.71 (brs,1H,NH) and ¹³C-NMR δ 12.9 (CH₃), 15.7 (CH₃), 31.5 (CH₂),49.5 (CH), 50.5 (CH₂),60.5 (CH₂), 101.3 (CH), 126.8 (C), 131.2(2CH),134.2 (2CH) ,137.7 (C) , 140.7 (C) 153.4(C) , 155.7(C) , 164.7(C) .Anal.Calc. For C₁₇H₂₀BrN₅O: C 52.32, H 5.17; found: C 52.48, H 5.24. MS:m/z 392[M+2],390[M],330 ,236,156,95.

2.1.35. 6-(4-bromophenyl)-3-(2-morpholin-4-yl-ethylamino)-4-(3, 5-dimethyl-pyrazol-1-yl)-4, 5-dihydropyridazin-3(2H) one 18

A mixture of 17 (5.90 g; 0.01 mol) ,morpholine (1.3 g ; 0.01 mol) and conc HCl (0.5 mL) in ethanol(20 mL) and was heated under reflux for 3h. The reaction mixture was concentrated under vacuum. The solid that separated was washed,filtered,dried and recrystallized from ethanol.

Yield 83%.Mp 130-132 °C. 1632 (C=N), 3298 (NH). ¹HNMR (DMSO-d₆) : δ 2.05 (s,3H, CH₃), 2.12 (s,3H, CH₃), 2.40-2.46 (m,4H,2CH₂N) , 3.40 (t,2H,CH₂-morph.,J=6.1),3.51 (t,2H,CH₂-N,J=6.1),3.77 (2dd,1Ha,(J=15.2,J=7.9) and 1Hb methylene protons , CH₂-

C=O, (J=15.2, J=2.4) diastereotopic protons), 3.7 (m,4H,2CH₂O) 4.84 (brs,1H,OH), 5.37 (dd,CH-COO,sterogenic methine proton , J=7.9,J=2.4),5.76 (s,1H,CH-pyrazol) ,7.33 (d,2H J=8.1,Ar-H), 7.76(d,2H, J=8.1,ArH) ,8.71 (brs,1H,NH) and 13C-NMR δ 12.9 (CH₃), 15.7 (CH₃), 32.5 (CH₂),44.5 (CH₂), 52.5 (CH),56.5 (2CH₂), 57.4 (CH₂), 67.8 (2CH₂), 100.9 (CH), 126.4 (C), 130.2(2CH),133.2 (2CH) ,137.7 (C) , 140.2 (C) 153.4(C) , 156.7(C) , 163.7(C).Anal.Calc. For C₂₁H₂₇BrN₆O: C 54.91, H 5.92; found: C 55.08, H 5.94. MS:m/z 461[M+2],459[M],330 ,236,156,95.

2.1.36. 6-(4-bromophenyl)-4-(3, 5-dimethyl-pyrazol-1-yl)-2-piperidin-1-ylmethyl, 5-dihydropyridazin-3(2H) one 19

A mixture of 15a(3.47 g;0.01 mol), piperidine (1 mL,0.015mol) and formaldehyde (1 mL) in ethanol (30 mL) and was stirred at room temperature for 5 min. and few drops of HCl was added.The reaction mixture was refluxed for 6h. The excess solvent was removed by vacuum distillation, and the separated product was washed,filtered,dried and was crystallized from ethanol.

Yield72%.Mp 185-187 °C. IR(KBr) 1682 (CO).¹HNMR (DMSO-d₆) : δ 1.17-1.27 (m,6H,3CH₂ piperidine moiety), 2.17 (s,6H,2CH₃), 1.37 (m,4H,2CH₂(pip) 3.92 (2dd,1Ha,(J=15.2,J=7.9) and 1Hb methylene protons , CH₂-C=O, (J=15.2, J=2.4) diastereotopic protons), 5.37 (dd,CH-COO,sterogenic methine proton , J=7.9,J=2.4),5.96 (s,1H,CH-pyrazol) ,7.33 (d,2H J=8.1,Ar-H), 7.76(d,2H, J=8.1,ArH) , and 13C-NMR δ 13.9 (CH₃), 15.7 (CH₃),23.4 (CH₂),26.5 (CH₂), 28.5 (CH₂),51.5 (2CH₂),55.3(CH₂),77.4 (CH₂),102.3 (CH), 129.8 (2C), 131.2(2CH),140.2 (2CH) ,154.7 (CH) , 159.7 (2C) 163.4(C) 165.7(C).Anal.Calc. for C₂₁H₂₆BrN₅O : C 56.76,H 5.90;found: C 56.45 , H 5.86. MS:m/z 346[M-C₆H₁₂N],281 ,224,191,156,84.

2.1.37. Compounds 20, 21

A mixture of 15c (4.11 g; 0.01 mol), ethylchloroformate 5 mL or ethyl chloroacetate 6.13 g (0.05mol) and anhydrous K₂CO₃ (5 g; 0.04 mol)in dry acetone (60 mL) and was refluxed for 24h.Excess solvent was removed by distillation. The reaction mixture was partitioned between H₂O and diethyl ether 3 x 30 mL. The combined organic extracts were dried by anhydrous sodium sulphate and the separated products dried and were recrystallized from ethanol.

2.1.38. 6-(4-bromophenyl)-4-(3methyl-5-oxo-4, 5-dihydropyrazol-1-yl)-2-ethoxy carbonyl-4, 5-dihydropyridazin-3(2H) one 20

Yield 74%.Mp 110-112 °C. IR (KBr) 1696, 1753. ¹HNMR (CDCl₃) : 1.21 (t,3H, CH₃,J=8.7) , 3.17 (s,2H,CH₂ of pyrazol), 3.86 (2dd,1Ha,(J=15.2,J=7.9) and 1Hb methylene protons , CH₂-C=O, (J=15.2, J=2.4) diastereotopic protons), 4.16 (q,2H.OCH₂,J=8.7),4.47 (dd,CH-COO,sterogenic methine proton , J=7.9,J=2.4),7.23 (m,9H,Ar-H), and 13C-NMR δ 15.7 (CH₃), 37.4 (CH₂),44.7 (CH₂),53.6 (CH), 64.7 (CH₂),123.3(CH), 127.4 (2CH),129.3 (2CH), 130.4 (2CH),131.3 (2CH), 138.8 (C), 148.2(2C),161.2 (2C) ,163.7 (C) , 165.4(C) , 167.8(C).Anal.Calc. For C₂₂H₁₉BrN₄O₄: C 55.75, H 3.83; found: C 55.58, H 3.62. MS:m/z 411[M-(CO₂+CH₂=CH₂)],270,193,156,95

2.1.39. 6-(4-bromophenyl)-4-(3methyl-5-oxo-4, 5-dihydropyrazol-1-yl)-2-ethoxy carbonyl-4, 5-dihydropyridazin-3(2H) one 21

Yield 70%.Mp 120-121 °C. IR(KBr) 1685,1734 . ¹HNMR (CDCl₃) : 1.23 (t,3H, CH₃,J=6.7), 3.23 (s,2H,CH₂ of pyrazol), 3.93 (2dd,1Ha,(J=15.2,J=8.1) and 1Hb methylene protons , CH₂-C=O, (J=15.2, J=2.4) diastereotopic protons), 4.16 (q,2H.OCH₂,J=6.7),4.67 (dd,CH-COO,sterogenic methine proton , J=8.1,J=2.4),5.2 (s,2H,N-CH₂-CO),7.43-7.72 (m,9H,Ar-H), and. 13C-NMR δ 13.7 (CH₃), 32.4 (CH₂),45.7 (CH₂),47.6 (CH₂), 52.7 (CH), 66.6 (CH₂), 123.3(C), 124.4 (2CH),125.3 (2CH), 128.4 (CH),129.3 (2CH), 130.8 (2CH), 136.2(C),138.2 (C) ,153.1(C) , 157.4(C) , 162.8(C) , 166.4(C) , 168.8(C).Anal.Calc. For Anal.Calc. For C₂₃H₂₁BrN₄O₄: C 55.54, H 4.26; found: C 55.65, H 4.43. MS:m/z 499[M+2],497[M],411,331,254,159.

2.1.40. 6-(4-bromophenyl)-4-(3methyl-5-oxo-4, 5-dihydropyrazol-1-yl)-2-hydrazino carbonyl-4, 5-dihydropyridazin-3(2H) one 22

A mixture of 20 (4.2 g; 0.01 mol) and hydrazine hydrate (1 mL, 0.015mol) in ethanol (30 mL) and was refluxed for 3h. The reaction mixture was allowed to cool and the separated product was filtered,dried and were recrystallized from ethanol.


Yield 82%.Mp 218-220 °C. IR (KBr) 1650 (C=N), 1676(CO). ¹HNMR (DMSO-d₆) : 3.17 (s,2H,CH₂ of pyrazol), 3.56 (2dd,1Ha,(J=15.2,J=7.9) and 1Hb methylene protons , CH₂-C=O, (J=15.2, J=2.4) diastereotopic protons), 4.06 (brs,1H,NH)4.47 (dd,CH-COO,sterogenic methine proton , J=7.9,J=2.4),7.23 (m,9H,Ar-H), 10.2 (s,2H,NH₂) and 13C-NMR δ 37.4 (CH₂), 53.6 (CH), 64.7 (CH₂),123.3(2CH), 127.4 (2CH),129.3 (2CH), 130.4 (2CH),131.3 (CH), 138.8 (C), 148.2(2C),161.2 (2C) ,163.7 (2C) , 165.4(C) , 167.8(C).Anal.Calc. For C₂₁H₂₁BrN₄O₄: C 55.75, H 3.83; found: C 55.58, H 3.62. MS:m/z 475[M+2],473[M],333,193,156,105.

3. Results and Discussion

Reports from our laboratory [11]-[17] and others[18,19] revealed that the β-aroyl acrylic acids are convenient poly electrophilic reagents in the synthesis of heterocycles, which for the addition reaction of nucleophililes e.g.carbon,nitrogen,sulfur, phosphore occurs exclusively at the α-carbon electrophilic center of the carboxy precursors.With the aim of broadening the synthetic potential of β-aroyl acrylic acids ,the authors can be reported the behavior of 3-(4-bromobenzoyl) prop -2- enoic acid 1 that was allowed to react with pyrazoles e.g.3,5-dimethylpyrazole,3-methyl/phenyl-2-pyrazolen-5-one in different reaction conditions,firstly in boiling ethanol (neutral medium) afforded the aza-Michael products 2-(3,5-dimethyl,3-methyl/phenyl-5-oxo- pyrazol-1-yl) 3(4-bromobenzoyl) propanoic acids 2a-c, where the reaction involving the N-alkylation of pyrazole moieties .But , when the acid 1 is submitted to react with 3-phenyl(1H)pyrazol-5(4H)-one in the presence of sodium hydroxide (basic medium) afforded 2-(5-oxo-3-phenyl-4,5-dihydro(4H)pyrazol-4-yl)-3-(4-bromobenzoyl) propanoic acid 3 , via the formation of


carbanion in the pyrazoline moiety that added to the activated double bond of the acid 1, C-alkylation for substituted pyrazole takes place under Michael reaction condition. For purpose of comparison, when the above reaction is conducted in the presence of anhydrous aluminum chloride (Lewis acid) in boiling benzene (acidic medium), it yielded 2-(5-hydroxy-3-phenyl-4,5-dihydro (4H) pyrazol-4-yl)-3-(4-bromobenzoyl)

propanoic acid (4) under Friedel-Crafts condition. One explanation for this phenomenon is that C-alkylation will be formed by the substitution reaction on the pyrazole moiety. The substitution product 4 is inferred chemically from another isolated product, furo [2, 3-c] pyrazole 5 that can be formed by dehydration of the product 4 (Scheme-1).



Also, when 3-(4-bromobenzoyl) prop-2-enoic acid 1 was allowed to react with cyclohexanone and /or camphor in the presence of sodium hydroxide (basic medium) under Michael reaction conditions afford the

adduct 6. The structures 6 can be confirmed chemically by interaction with hydrazine derivatives afforded 1,2-diazapine derivatives 7 and 8 as outlined in scheme 2.




The 3-aryl propio-2-enoic acids, when allowed to react with nitrogen containing binucleophiles [12]-[14]. The reactivity of C2 in 3-(4-bromobenzoyl) propio-2-enoic acids are enable to allow aza-michael addition by phenylene diamine and 2-methyl-4(3H) quinazolinone derivatives in ethanol (protic solvent) afford acids 9. The presence of different kinds of electrophilic centers in intermediate products 9 lead to the possible formation of six membered heterocycles. The intermediate 9i can be dehydrated spontaneously to afford the dihydroquinoxalin-2-one derivative 10, but the pyrido [2, 1-b] quinazolinone

derivative 11 can be formed via interaction of the isolated adducts 9b with sodium methoxide in methanol under Michael condition. On the other hand, when the acid 1 was allowed to react with 2-methylquinazolinone in acetonitrile (aprotic solvent) yielded pyrido [1,2-a] quinazolinone derivatives 12 Scheme 3. The products 11 and 12 afforded according to the reaction medium, the base catalyzed of the N-alkylation adduct 9b could form carbanion intermediate that stabilized in protic solvent followed by ring closure to yield 11. Opposing the formation of adduct 12, C-alkylation of the active methyl


group of quinazolinone nucleus followed by ring closure upon N1 instead of N3 via the route iii (scheme 4). The electrocyclization by this way due to, in aprotic solvent the quinazolinone moieties are major in lactim tautomer and

the electron density on N1 was increased by the phenolic group in the position 4. So, they can be isomerized to the thermodynamically more stable 12.



The quinoxalinone plays an important role in organic synthesis [21], displaying a broad spectrum of biological activities [22], as a building blocks in the synthesis of organic semiconductors [23]. So, the authors can be interested in developing the precursors 10. Also, 2 (3H) furanone as a new antioxidant and anti-inflammatory agent, the recent efforts devoted to the development of new ascorbic acid analogues have resulted in obtaining anti-oxidant, [24]–[29], anti-tumoral [30], when the acids 2 were allowed to react with acetic anhydride on heating water bath for 1h, they have 5-(p-bromophenyl)-3-

substituted pyrazol-1-yl)-2-(3H) furanone (13) (Scheme 4). To continue in our research, the different kinds of electrophilic centers in the acids 1 that can be reacted with simply binucleophiles e.g. hydroxylamine and hydrazine hydrate to afford an important heterocycles. Oxazinone derivatives are an important clan of heterocyclic compounds, since many of their heterocyclic system exhibit biological activity [31]. Thus, when the acid 2 was allowed to react with hydroxylamine hydrochloride in boiling pyridine afford oxazinone derivative 14.




Synthetic 3(2H) pyridazinones are important scaffolds in drug discovery, with many of their analogs being in the treatment of various human pathological states. They were

described nonsteroidal anti-inflammatory drugs e.g. Emorfazone and related compounds [32] agents for therapeutic intervention of renal urologic e.g. FK-838

[33],cardiovascular e.g.EMD-57283 [34] , respiratory e.g. NIP-502[35] and dermatologic diseases e.g. FR-1818177 [36], pyridazinone PDE inhibitors developed from ibudilast [37]. The design of a new prepared compounds based on the structure contain other biologically actives heterocycles on the side chains [38] It reported in the field of cancer therapy that pyrazoles[39,40] enhances the biological profile many fold than their parent nuclei.This


prompted us to continuo [10]-[14] the prepare some interesting heterocyclic compounds e.g.pyrazole derivatives incorporated with pyridazinone nucleus in position 4 . Thus, when acids 2 a-c were allowed to react with hydrazine hydrate in boiling ethanol , they afforded 6- bromophenyl- 4 (substituted pyrazol-1-yl) 2,3,4,5 tetrahydro 3(2H) pyridazinones (15) Scheme 5.



Scheme 5


Also,treatment of 15a with phosphorous pentachloride in the presence of phosphrous oxychloride on warming water bath afforded the 3-chloro derivatives 16. Herein, nucleophilic substitution of the chloropyridazine derivative 16 with ethanol amine yielded 3-(2-hydroxyethylamino)-pyridazine derivative 17. The structure of compound 17 is inferred chemically by its reaction with morpholine in the

presence of a few drops of HCl gave the Mannich type reaction product 18. On the other hand, the pyridazinone 15a was submitted to react with formaldehyde in the presence of piperidine in boiling methanol under Mannich reaction conditions, it yielded the 2-(N-piperidomethyl)pyridazin-3(2H)-one 19 Scheme 6.



Thereafter,when compound 15c was allowed to react with ethyl chloro formate and ethylchloro- acetate in boiling acetone in the presence of anhydrous potassium carbonate in accordance with reported method for electrophilic substitution of lactam form [41]yielded ethyl 2-(3-(4-bromophenyl)-6-oxopyridazin-1(6H)yl) formate

and / or acetate (20 and 21) respectively (Scheme 7) .IR spectrum revealed strong absorption bands a(1754,1670 cm-1) attributable to two ν CO and devoid any band for ν NH .



Scheme 7

From the spectroscopic tools, the reaction possibly takes place via N-alkylation e.g. SN₂ mechanism with ethyl chloro acetate but tetrahedral mechanism with ethyl chloro formate while acid chloride is more reactive than ester group i.e. chloride anion is good leaving group than ethoxy group. Hydrazinolysis of the ester 20 via interaction with hydrazine hydrate yielded the corresponding hydrazide 22 (Scheme 7).

4. Conclusion

The present work is succeeded to study the effect of the medium pH on the type of Michael addition (Michael or Aza-Michael) beside studying the behavior of 3-(4-bromo benzoyl)prop-2-enoic acid towards nitrogen and carbon nucleophiles producing a series of some important heterocycles and for the first time, synthesis of oxazinone and pyridazinone derivatives bearing 4-heteryl moiety inside to aromatic substituents in the position 6 that enhances the biological profile many fold than their parent nuclei

Acknowledgment

The authors are thankful to Prof. Dr. Eilbracht, Dortmund Technological University, Germany, for providing H-NMR and C-NMR spectral data

References

- Z. Juranic, L. J. Sterovic, B. Darkulic, T. Stanojkovic, S. Radulovic and I. "Juranic," J Serb Chem Soc., 1999, 64, pp. 505.
- L. M. Taaylor, J. A. Aquilina, J. F. Jamie, and R. J. W. Truscott, Ex Eye Res., 2002, 75, pp. 165.
- A. Volonterio, C. R. Arellano, and M. Zanda, J Org Chem., 2005, 70, pp. 2161.
- T. Kohler, G. Friedrich, and P. Nuhn, Inflamm Res., 1991, 32, pp. 115, 346.
- F. K. Krichner, J. H. Bailey, and C. Cavallito, J Am Chem Soc., 1949, 71, 1210.
- H. Takayanagi, Y. Kitano, T. Yano, H. Umeki, H. Hara, Can Patent Appl., 2,114,333, 1994. C.A. 1995, 122, 1042.
- S. J. Gharpure, and S. R. B. Rddy, Org Lett., 2009, 11, pp. 2519.
- A. K. Atta, and T. Pathak, Eur J Org Chem., 2010, pp. 6810.
- M. M. El-Mobayed, A. M. Hassein, and W. M. Mohlhel, J Heterocyclic Chem., 2010, 47, pp. 534.
- K. K. Jha, Y. Kumer, Mohd. Shaharyar, and G. Sharma, Asian J Chem., 2009, 21, pp. 6491.
- S. A. Rizk, M. A. El-Hashash, M. M. Aburzeza, "1,4-Arylation of β -(4-acetylaminobenzoyl)acrylic Acid with Activated Aromatic Hydrocarbons under Friedel-Crafts Conditions and Some Studies with the Products," Egypt J Chem., 2011, 54, 1.
- S. A. Rizk, M. A. El-Hashash, "2-(3,4-dimethylphenyl)-[3,4-dichloro (or 3,4-dimethyl) benzoyl]-propanoic acids as Precursors in the Synthesis of Some Heterocyclic Compounds," Egypt J Chem., 2011, 54, 5.
- S. A. Rizk, M. A. EL-Hashash, and M. M. Aburzeza, "Utility of p-Acetamidobenzoyl Prop-2-enoic Acid in the Synthesis of New α -Amino Acids and Using them as Building Blocks in Heterocyclic Synthesis," Egypt J Chem., 2011, 54, 3.
- M. A. El-Hashash, G. A. Abdel-Mageid, S. S. El-Kady, and S. A. Mohammed, Egypt Chem., 2008, 51(1), pp. 103-112.
- S. A. Rizk, M. A. El-Hashash, K. K. Mostafa, "Utility of β -Aroyl Acrylic acid in Heterocyclic Synthesis. Egypt, J. Chem., 2008, 51(5), pp. 116-121.
- A. S. Youssef, H. F. Madkour, M. I. Marzouk, A. M. El-Soll, M. A. El-Hashash, "Utility of 3-Aroyl prop-2-enoic acid in Heterocyclic Synthesis," Afinidad., 2003 61(512), pp. 304-316
- A. S. A. Yousef, M. I. Marzouk, H. M. F. Madkour, A. M. A. El-Soll, M. A. El-Hashash, "Synthesis of Some Heterocyclic system of anticipated biological activities via 6-aryl-4-pyrazol-1-yl-pyridazin-3-one," Can J Chem., 2003 83(251), pp. 304
- M. Umpreti, S. Pant, and A. Dandia, Phosphorous, Sulfur, Silicon, 1996, 113, pp. 165.
- R. D. Khachikyan, N. V. Karamyan, G. A. Panosyan, M. G. Indzhikyan, I. Z. V. Akad. Nauk. Ser. Khim, 2005, pp. 1923.
- N. H. Cromwell, K. E. Cook, P. Creger, J Am Chem Soc., 1956, 78, pp. 4412.
- V. M. Shivaji, M. N. Sastry, C. C. Wang, Y. Ching-Fa, Tetrahedron Lett., 2005, 46, pp. 6354.
- N. Sato in A. R. Katritzky, C. W. Rees, S. Craven (Eds), Comprehensive Heterocyclic Chemistry 1996 II, vol. 6 Pergamon, Oxford, p. 233.
- G. Sakata, K. Makino, Y. Kurasama, Heterocycles., 1988, 27, pp. 2481.
- L. E. Seitz, W. J. Suling, R. C. Reynolds, J Med Chem. 2002, 45, pp. 5604.
- T. Uxey, P. Tempest, and C. Hulme, Tetrahedron Lett., 2002, 43, pp. 1637.
- S. A. Khan, P. Mullick, S. Pandit, and D. Kaushik, "synthesis of hydrazones derivatives of quinoxalinone prospective antimicrobial and antiinflammatory agents," Acta Poloniae Pharmaceutica Drug Research., 2009, 66(2) pp. 169-172
- S. Dailey, J. W. Feast, R. J. Peace, I. C. I. Sage, S. Till, and E. L. Wood, J Material Chem., 2001, 11, pp. 2238.
- P. Cotelle, N. Cotelle, E. Teissier, and H. Vezin, Bioorg. Med Chem., 2003, 11, pp. 1087-1093.
- V. Weber, P. Coudert, C. Rubat, E. Duroux, J. C. Vallee-Gramain, J. Couquelet, and M. Madesclaire, Bioorg Med Chem. 2002, 10, pp. 1647.

- [30] V. Weber, P. Coudert, C. Rubat, E. Duroux, F. Leal, J. Couquelet, *J Pharm Pharmacol.*, 2000, 52, pp. 523
- [31] S. Manfredini, S. Vertuani, B. Manfredi, G. Rossini, G. Calviello, P. Palozza, *Bioorg Med Chem.*, 2000, 8, pp. 2791.
- [32] T. Mashino, Y. Takigawa, N. Saito, L. Q. Wong, M. Mochizuki, *Bioorg Med Chem Lett.*, 2000, 10, pp. 2783.
- [33] V. Weber, C. Rubat, E. Duroux, C. Lartigue, M. Madesclairea and P. Couderta, "New 3- and 4-hydroxyfuranones as anti-oxidants and anti-inflammatory agents," *Bioorganic & Medicinal Chemistry.*, 2005, 13 pp. 4552–4564.
- [34] S. Raic-Malic, D. Svedruzic, T. Gazivoda, A. Marunovic, A. Hergold-Brundic, A. Nagl, J. Balzarini, E. DeCl-ercq, M. Mintas, *J Med Chem.*, 2000, 43, pp. 4806.
- [35] M. Patel, R. J. J. McHvgh, B. C. Cardova, R. M. Klabe, S. Ericksonviitanen, G. L. Trainor, S. S. Ko, *Bioorg Med Chem Lett.*, 1999, pp. 3221.
- [36] H. A. EL-Shafei, S.M. BadrEldin, *Egypt J Microbiol.*, 1994, 27, pp. 353.
- [37] A. Akahane, H. Katayama, T. Mitsunaga, T. Kato, A. Kinoshita, Y. Kita, T. Kusaunoki, Terai, K. Yoshida, and Y. Shiokawa, *J Med Chem.*, 1999, 42, pp. 779.
- [38] H. Horino, T. Mimura, K. Kagechika, M. Ohta, H. Kubo, M. Kitagawa, *Chem Pharm Bull.*, 1998, 46, pp. 402.
- [39] A. Yamamoto, T. Iwama, H. Takeda, H. Nagai, *Jpn J Pharmacol.*, 1995, 68, pp. 47.
- [40] K. Tsubaki, K. Taniguchi, S. Tabuchi, O. Okitsu, K. Hahori, J. Soki, K. Sakane, and H. Tanaka, *Bioorg Med Chem Lett.*, 2000, 12, pp. 2787.
- [41] R.W. Allcock, H. Blakli, Z. Jiang, K. A. Johnston, K. M. Morgan, G. M. Rosair, K. Iwase, Y. Kohno, D. R. Adams, "Phosphodiesterase inhibitors. Part 1: Synthesis and structure-activity relationships of pyrazolopyridine-pyridazinone PDE inhibitors developed from ibudilast," *Bioorganic & Medicinal Chemistry Letters.*, 2011, 21, pp. 3307–3312.
- [42] K. Kesharwani, N. K. Sahu, and D.V.J. Kohli, *pharma Chem.* 2009, 43, pp. 6.
- [43] I. Bouabdallah, L. A. Berek, A. Zayed, A. Ramadani, I. Zidane, A. Melhaoui, "Anticancer effect of three pyrazole derivatives natural product reseach, 2006, 20(11) pp. 1024, DOI:10.10180/14786410600921441.
- [44] A. Abadi, A. A.Eissa and G. S. Hassan, "Synthesis of novel 1,3,4-trisubstituted pyrazole derivatives and their evaluation as antitumor and antiangiogenic agents," *Chem Pharm Bull.*, 2003, 51(7), pp. 838.
- [45] M. A. El-Hashash, Y. A. El-Badry, *Helv Chem Acta.*, 2011, DOI:10.1002/hlca.20100023